This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pluristem's CEO Letter To Shareholders

In the pulmonary area, we were able to improve lung function and reduce the pulmonary fibrosis that occurs in Interstitial Lung Disease (ILD). In the cardiac area, we have demonstrated that the cardiac function in diabetic animals with heart failure was improved by using our PLX cells.

Enhancing our IP position

During 2012 we have invested significant efforts in strengthening our IP position. We have filed several new patent families covering new indications, new devices and manufacturing processing. We were also granted several patents and filed new applications at the National Phase stage. As of December 2012, all of this activity has led to Pluristem fully owning 22 granted patents and 95 pending applications.

Insured financial soundness and inclusion into the Tel Aviv 75 and 100 indices

We are very proud to be included in the Tel Aviv 75 and Tel Aviv 100 indices. The TA-100 Index is one of the TASE's leading indices and is comprised of the shares of the 100 largest Israeli companies ranked by market capitalization. As a result, we now have exposure with more institutional, long-term investors who are now able to invest in our stock due to our inclusion in these indices. This is a good step in the right direction for our company as we look to bring in more institutional investors to become long-term shareholders of our stock. During 2012 we raised $34 million net in a secondary offering. With our strong cash position of approximately $65M with no debt, we are well positioned to support our research and development as well as our clinical programs with a goal of bringing PLX cells to the market for several indications.

Constructing new "state-of-the-art" manufacturing facility for our PLX Cells

We have recently initiated the final validation steps for our new Good Manufacturing Process (GMP) facility prior to taking possession. I am extremely proud of our team in meeting milestones for the completion of this state of the art facility. We have also been hard-at-work optimizing our manufacturing process, including the scale up and automation processes, to accommodate the potential future commercial production of our PLX cells. We have initiated the "integral runs" that incorporate all the scale up and automation processes into a seamless production line. These "integral runs" will enable us to move the production line into our new manufacturing facility effectively.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs